<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>23</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Independent and Additive Interaction Between Tumor Necrosis Factor β +252 Polymorphisms and Chronic Hepatitis B and C Virus Infection on Risk and Prognosis of Hepatocellular Carcinoma: a Case-Control Study</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>10209</FirstPage>
			<LastPage>10215</LastPage>
			<ELocationID EIdType="pii">30245</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>To assess the contribution of tumor necrosis factor (TNF)β +252 polymorphisms to risk and prognosis ofhepatocellular carcinoma (HCC), we enrolled 150 pairs of sex- and age-matched patients with HCC, patientswith cirrhosis alone, and unrelated healthy controls. TNFβ +252 genotypes were determined by polymerasechain reaction with restriction fragment length polymorphism. Multivariate analysis indicated that TNFβ G/Ggenotype [odds ratio (OR), 3.64; 95%CI, 1.49-8.91], hepatitis B surface antigen (OR, 16.38; 95%CI, 8.30-32.33),and antibodies to hepatitis C virus (HCV) (OR, 39.11; 95%CI, 14.83-103.14) were independent risk factors forHCC. There was an additive interaction between TNFβ G/G genotype and chronic hepatitis B virus (HBV)/HCVinfection (synergy index=1.15). Multivariate analysis indicated that factors associated with TNFβ G/G genotypeincluded cirrhosis with Child-Pugh C (OR, 4.06; 95%CI, 1.34-12.29), thrombocytopenia (OR, 6.55; 95%CI,1.46-29.43), and higher serum α-fetoprotein concentration (OR, 2.53; 95%CI, 1.14-5.62). Patients with TNFβG/G genotype had poor cumulative survival (p=0.005). Cox proportional hazard model indicated that TNFβ G/Ggenotype was a biomarker for poor HCC survival (hazard ratio, 1.70; 95%CI, 1.07-2.69). In conclusion, thereare independent and additive effects between TNFβ G/G genotype and chronic HBV/HCV infection on risk forHCC. It is a biomarker for poor HCC survival. Carriage of this genotype correlates with disease severity andadvanced hepatic fibrosis, which may contribute to a higher risk and poor survival of HCC. Chronic HBV/HCVinfected subjects with this genotype should receive more intensive surveillance for early detection of HCC.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Tumor necrosis factor β polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Hepatocellular carcinoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Susceptibility</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognosis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30245_79ffbbe9ebfe3b35f57218084ce37eb7.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
